The Global GLP-1 Market Strategic Intelligence Suite 2026-2031 combines two full-length strategic research reports -- the Global GLP-1 Drug Market Report (demand-side, USD 70.58 billion in 2025, 12.8% CAGR to USD 145.39 billion by 2031) and the Global GLP-1 Drug Manufacturing & Supply Chain Market Report (supply-side, USD 45.0 billion in 2025, 26.0% CAGR to USD 180.0 billion by 2031) -- plus a cross-report executive presentation, summary document, and interactive infographic.
The GLP-1 category shows one of the widest demand/supply growth-rate divergences of any pharmaceutical sub-sector currently tracked -- manufacturing capacity value is forecast to overtake drug-market revenue by 2031. This Suite bundles both reports with cross-report analysis including the tirzepatide/semaglutide leadership reversal (Eli Lilly's 57% US market share, USD 1 trillion market cap milestone), and the real, quantified reshoring wave (USD 18.48 billion of USD 24.86 billion in 2025 CDMO investment directed to non-China facilities).
A reader evaluating GLP-1 exposure -- whether for capacity investment, competitive positioning, or portfolio analysis -- needs both the manufacturing-side capacity race and the consumption-side revenue realization to understand the full picture.
The GLP-1 category shows one of the widest demand/supply growth-rate divergences of any pharmaceutical sub-sector currently tracked -- manufacturing capacity value is forecast to overtake drug-market revenue by 2031. This Suite bundles both reports with cross-report analysis including the tirzepatide/semaglutide leadership reversal (Eli Lilly's 57% US market share, USD 1 trillion market cap milestone), and the real, quantified reshoring wave (USD 18.48 billion of USD 24.86 billion in 2025 CDMO investment directed to non-China facilities).
A reader evaluating GLP-1 exposure -- whether for capacity investment, competitive positioning, or portfolio analysis -- needs both the manufacturing-side capacity race and the consumption-side revenue realization to understand the full picture.
Scope of Global GLP-1 Market Strategic Intelligence Suite 2026-2031
- This Suite includes the complete Global GLP-1 Drug Market Strategic Research Report.
- This Suite includes the complete Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report.
- This Suite includes a 12-slide executive presentation comparing both reports' key findings.
- This Suite includes a cross-report summary document explaining the capacity-constraint linkage.
- This Suite includes an interactive infographic for board-level and investor-facing use.
- This Suite covers 12 unique companies across both underlying reports.
Who can use the Global GLP-1 Market Strategic Intelligence Suite?
This Suite is ideal for people who need both sides of the GLP-1 value chain in one integrated resource. Some of the intended users are:- Investors evaluating full GLP-1 value-chain exposure across manufacturing and commercial positioning
- CDMOs and manufacturing capacity planners evaluating investment against real demand growth
- C-level executives requiring comprehensive GLP-1 strategic intelligence for board presentations.
Table of Contents
1. Suite Overview2. Report 1: Global GLP-1 Drug Market (full 13-chapter report)
3. Report 2: Global GLP-1 Drug Manufacturing & Supply Chain Market (full 13-chapter report)
4. Suite Bonus Deliverables (Executive Presentation, Summary Document, Infographic)
Companies Mentioned
- Eli Lilly and Company
- Novo Nordisk A/S
- Biocon Biologics
- Amgen Inc.
- Viking Therapeutics
- Zealand Pharma A/S
- Hanmi Pharmaceutical Co.
- Roche / Genentech
- Novo Holdings (via Catalent)
- Samsung Biologics
- Lonza
- WuXi Biologics
